Osteogenic biphasic calcium sulphate dihydrate/iron-modified alpha-tricalcium phosphate bone cement for spinal applications: in vivo study.
In this study, the biocompatibility and the osteogenic features of a new iron-modified alpha-tricalcium phosphate (IM/alpha-TCP) and calcium sulphate dihydrate (CSD) biphasic cement (IM/alpha-TCP/CSD-BC) have been investigated in terms of the in vivo cement resorption, bone tissue formation and host tissue response on sheep animal model. Histological evaluation performed on undecalcified cement-bone specimens assessed the in vivo behaviour. It has been shown that the new IM/alpha-TCP/CSD-BC has the ability to produce firm bone binding in vivo (i.e. bioactivity). Qualitative histology proved cement biocompatibility, osteoconduction and favourable resorption, mainly through a macrophage-mediated mechanism. The results showed that the new cements have biocompatible and osteogenic features of interest as possible cancellous bone replacement biomaterial for minimally invasive spinal surgery applications.
Vlad
M D
MD
Interdepartment Research Group for the Applied Scientific Collaboration (IRGASC), Division of Biomaterials & Bioengineering, Technical University of Catalonia (UPC), Avda. Diagonal 647, Barcelona, Spain.
Sindilar
E V
EV
Mariñoso
M L
ML
Poeată
I
I
Torres
R
R
López
J
J
Barracó
M
M
Fernández
E
E
D000818:Animals; D001672:Biocompatible Materials; D001843:Bone Cements; D002130:Calcium Phosphates / Q000008:administration & dosage* / Q000737:chemistry; D002133:Calcium Sulfate / Q000008:administration & dosage*; D005260:Female; D007501:Iron / Q000737:chemistry*; D012756:Sheep; D013131:Spine / Q000601:surgery*
D001672:Biocompatible Materials; D001843:Bone Cements; D002130:Calcium Phosphates; D007501:Iron; C018392:tricalcium phosphate; D002133:Calcium Sulfate